Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Portaccio E, Stromillo M, Goretti B, Hakiki B, Giorgio A, Rossi F, De Leucio A, De Stefano N, Amato MP Eur J Neurol. 2012 Oct 11. PMID: 23057658. Abstract CommentRecommendBookmarkWatch